Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark.

Anders Muusfeldt BirckLiv Nordin ChristensenMikkel Hasse PedersenJens OlsenKelly D JohnsonGoran BencinaThomas Holtkøtter ClausenCarsten Schade Larsen

Published in: Expert review of vaccines (2021)

The recent introduction of the age-based vaccination programme offering PPSV23 vaccination to all persons aged 65+ in Denmark is cost-effective. This is also the case if the programme is extended to include persons aged 60-64.

Keyphrases

study protocol
healthcare
public health
mental health
clinical trial
climate change